Bonus Biogroup Ltd
TASE:BONS
Intrinsic Value
Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. [ Read More ]
The intrinsic value of one BONS stock under the Base Case scenario is 1.87 ILS. Compared to the current market price of 16 ILS, Bonus Biogroup Ltd is Overvalued by 88%.
Valuation Backtest
Bonus Biogroup Ltd
Run backtest to discover the historical profit from buying and selling BONS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bonus Biogroup Ltd
Current Assets | 33.2m |
Cash & Short-Term Investments | 32.8m |
Receivables | 370k |
Non-Current Assets | 19m |
PP&E | 18.6m |
Intangibles | 27k |
Other Non-Current Assets | 372k |
Current Liabilities | 5.4m |
Accounts Payable | 3.5m |
Other Current Liabilities | 1.9m |
Non-Current Liabilities | 10m |
Long-Term Debt | 10m |
Earnings Waterfall
Bonus Biogroup Ltd
Revenue
|
0
ILS
|
Operating Expenses
|
-32.9m
ILS
|
Operating Income
|
-32.9m
ILS
|
Other Expenses
|
1.9m
ILS
|
Net Income
|
-31m
ILS
|
Free Cash Flow Analysis
Bonus Biogroup Ltd
BONS Profitability Score
Profitability Due Diligence
Bonus Biogroup Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Bonus Biogroup Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
BONS Solvency Score
Solvency Due Diligence
Bonus Biogroup Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Bonus Biogroup Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BONS Price Targets Summary
Bonus Biogroup Ltd
Shareholder Return
BONS Price
Bonus Biogroup Ltd
Average Annual Return | 20.58% |
Standard Deviation of Annual Returns | 102.19% |
Max Drawdown | -92% |
Market Capitalization | 195.7m ILS |
Shares Outstanding | 12 231 650 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.
Officers
The intrinsic value of one BONS stock under the Base Case scenario is 1.87 ILS.
Compared to the current market price of 16 ILS, Bonus Biogroup Ltd is Overvalued by 88%.